IBN Receives Patent Approval for Eriocitrin Use in Blood Glucose Formulations

Excerpt from Nutrition Industry Executive

IBN announced approval by the USPTO of a patent for IBN's use of eriocitrin in its blood glucose management ingredient formulations, such as in Eriomin.

The patent number is 10596185, which was officially issued on March 24, 2020.

Read more about the new patent on page 23 of Nutrition Industry Magazine ยป